Видео с ютуба Fda Bioequivalence

Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA

FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence

A New Possible Way to Evaluate Bioequivalence of Topical Drugs

M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the FG (Condensed)

Bioequivalence Regulations and Product-Specific Guidances

Navigating First ICH Generic Drug Draft Guideline M13A Bioequivalence for IR Solid Oral Dosage Forms

Bioequivalence for Generic Topical and Transdermal (6of35) Complex Generics– Sep. 25-26, 2019

Best Practices for Conducting Bioequivalence Studies (16of27) Generic Drugs Forum 2018

Case Studies: Inadequate Bioequivalence Studies (18of28) Generic Drugs Forum – Apr. 3-4, 2019

M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance

GDF 2024 | D2S02 - GDSA-BE: Modernizing Bioequivalence Assessment for Abbreviated New Drug...

FDA Overview of ICH M13 Guideline Series Webinar (Bioequivalence Webinar)

FDA M13A Bioequivalence for Immediate-Release Solid Oral Dosage Webinar - Closing Remarks

GDF2025 - D2S03- Bioequivalence Approaches for Nitrosamine Impacted ANDA Applications: Case Studies

In vitro bioequivalence testing for topical ophthalmic suspension products (17of39) Complex Generics

In Vitro Release Testing for Complex Generics: A Bioequivalence Perspective

FDA M13A Bioequivalence for Immediate-Release Solid Oral Dosage Webinar - Question & Answer Panel

Data Integrity Issues in Bioequivalence Studies

FDA GDF 2025 - Request for Reconsideration: Overview and Experience from Bioequivalence Perspectives

FDA M13A Bioequivalence for Immediate-Release Solid Oral Dosage Webinar - Discussion Panel